Mesothelioma Survival Rates

Mesothelioma survival rates represent the percentage of patients who remain alive at specific time points after diagnosis. These statistics, drawn primarily from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, provide a population-level picture of outcomes for malignant mesothelioma. While survival rates have historically been low, meaningful improvements have emerged in recent years due to advances in immunotherapy, surgical techniques, and multimodal treatment approaches.¹

The overall 1-year survival rate for mesothelioma is approximately 40–50%, meaning that roughly half of all diagnosed patients are alive one year after diagnosis. The 3-year survival rate drops to approximately 10–20%, and the 5-year survival rate is estimated at 5–10%. These aggregate figures encompass all stages, cell types, and treatment approaches, meaning they may not accurately reflect any individual patient's specific situation.²

Survival rates vary dramatically based on several factors. Epithelioid mesothelioma has significantly better survival rates than sarcomatoid or biphasic subtypes. Peritoneal mesothelioma patients treated with cytoreductive surgery and HIPEC have 5-year survival rates approaching 50%, far exceeding the rates for pleural disease.³

The approval of nivolumab plus ipilimumab (CheckMate 743 trial) in 2020 for unresectable pleural mesothelioma has contributed to improving survival trends. Clinical trials continue to evaluate novel combinations and targeted therapies that may further improve these statistics. Patients should understand that survival rates are historical data and may not reflect the most current treatment advances. Early consultation with a mesothelioma attorney is also advisable, as legal deadlines run independently of treatment timelines.

Factors that influence mesothelioma survival rates at the population level include:

• Cell type — epithelioid mesothelioma has the highest survival rates across all time points
• Stage — localized disease (SEER localized stage) has a 5-year survival rate of approximately 18%, compared to 7% for regional and less than 3% for distant disease
• Mesothelioma site — peritoneal mesothelioma treated with HIPEC has markedly better survival than pleural disease
• Treatment received — patients who undergo surgery-based multimodal therapy have higher survival rates than those receiving chemotherapy alone
• Age and gender — younger patients and women have statistically higher survival rates
• Era of diagnosis — patients diagnosed in recent years benefit from newer treatment options and improved supportive care

Mesothelioma survival rates by SEER stage summary (all cell types combined):

• Localized (tumor confined to the primary site) — 5-year relative survival approximately 18%
• Regional (spread to nearby structures or lymph nodes) — 5-year relative survival approximately 7–12%
• Distant (metastasized to remote sites) — 5-year relative survival approximately 2–3%

Survival rates by cell type show striking differences. Epithelioid mesothelioma patients have 1-year survival rates exceeding 50%, while sarcomatoid patients have 1-year rates below 20%. The improving trend in overall survival is largely driven by the introduction of immune checkpoint inhibitors, which have shown particular benefit in non-epithelioid subtypes that were previously most resistant to treatment.⁴

Understanding survival statistics in context is important for patients and families:

• Survival rates are population averages — they do not predict individual outcomes
• Rates are based on historical data and may not reflect the most recent treatment advances
• Ask your oncologist to explain how your specific factors compare to published statistics
• Seek treatment at specialized mesothelioma centers with the best track records
• Consider clinical trials that may offer access to therapies not yet reflected in published survival data